Zeile 41: |
Zeile 41: |
| ==Quellennachweise== | | ==Quellennachweise== |
| <references/> | | <references/> |
− | * American Botanical Council: Ephedra. Published Jan. 17th 1991. http://www.herbalgram.org/ commission_e/ephedra.html | + | *http://www.innovations-report.de/html/berichte/medizin_gesundheit/bericht-16241.html |
− | * Fleming GA: The FDA, regulation and the risk of stroke. N Engl J Med, 343, 1886-1887, 2000, http://www.nejm.org/content/2000/0343/0025/1886.asp | + | *American Botanical Council: Ephedra. Published Jan. 17th 1991. http://www.herbalgram.org/ commission_e/ephedra.html |
− | * Gugliotta G: Dietary supplement makers flex muscle. $ 15 Billion industry fends off attempts to regulate ephedra over health risks. The Washington Post, Monday, 25th. Dec, 2000 http://washingtonpost. com/wp_dyn/articles/A47922-2000Dec24.html | + | *Fleming GA: The FDA, regulation and the risk of stroke. N Engl J Med, 343, 1886-1887, 2000, http://www.nejm.org/content/2000/0343/0025/1886.asp |
− | * Haller CA, Benowitz NL: Adverse cardiovascular and central nervous sytem events associated with dietary supplements containing ephedra alkaloids. 6.12.2000. http://www.nejm.com/content/haller/1.asp | + | *Gugliotta G: Dietary supplement makers flex muscle. $ 15 Billion industry fends off attempts to regulate ephedra over health risks. The Washington Post, Monday, 25th. Dec, 2000 http://washingtonpost. com/wp_dyn/articles/A47922-2000Dec24.html |
| + | *Haller CA, Benowitz NL: Adverse cardiovascular and central nervous sytem events associated with dietary supplements containing ephedra alkaloids. 6.12.2000. http://www.nejm.com/content/haller/1.asp |
| | | |
| {{Paralex}} | | {{Paralex}} |